Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today provided an update on ...
Boffins in Manchester have been studying the gene mutations of fruit flies to solve the riddle of what causes diseases like ...
PRNewswire/ -- (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today provided preliminary unaudited ...
Sidra Medicine has marked a significant medical achievement by securing regulated access to sepiapterin for patients with Phenylketonuria (PKU), positioning Qat ...
FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review processCompany expects to submit updates ...
Boyd Elementary School third-grader Micah Wilson monitored the hallways Friday with a walkie-talkie in her hands, making sure ...
In conjunction with the strategic evolution, the Company appointed Jian Irish, Ph.D., M.B.A., as Chief Executive Officer. Based on a revised capital allocation strategy, the Company extended its ...
Korro Bio, Inc. ( KRRO) 44th Annual J.P. Morgan Healthcare Conference January 15, 2026 1:30 PM EST ...
Victoria Gray spent 34 years battling the debilitating pain of sickle cell disease. Then she volunteered to be the world's first "prototype" for a CRISPR therapy, based on technology invented at UC ...
WAKIX 2025 Preliminary Net Revenue of ~$868 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in NarcolepsyOn Track to Extend the Pitolisant Franchise ...
MONTREAL, /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback